Hyperuricemia is caused by a defect in renal transport in about 98% of all those affected. These patients have reduced uric acid clearance, which combined with purinrich food raises plasma uric acid levels to hyperuricemic values. Hyperuricemia is defined according to the limit of solubility of monosodium urate in extracellular fluid at pH 7.4 and 37°C to 6.5 mg/dl and more. In industrialized countries about 30% of the men and 3% of the women suffer from hyperuricemia [5, 6]. Depending on the duration and extent of the disease, patients develop gouty arthritis and nephrolithiasis (Table 1). In most patients with hyperuricemia caused by a defect in renal transport gouty arthritis occurs first. Nephrolithiasis is the first symptom in the majority of the patients who are overproducers because of an enzyme defect such as HGPRT deficiency. Some of the other diseases associated with hyperuricemia are hyperlipidemia, hypertension, obesity, atherosclerosis, hyperglycemia, diabetes mellitus, and ethanol consumption.


Uric Acid Serum Uric Acid Uric Acid Level Gouty Arthritis Monosodium Urate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gathof BS, Schreiber MA, Gresser U, Kamilli I, Zöllner N (1991) Importance of the confounding factors age and sex in the correlation of serum uric acid, cholesterol and triglyceride levels. Adv Exp Med Biol 309A: 231–234Google Scholar
  2. 2.
    Gresser U (1990) Therapie von Hyperurikämie und Gicht mit Urikosurika. Mediscript-Verlag, MunichGoogle Scholar
  3. 3.
    Gresser U (1993) Fenofibrate: a lipid lowering drug with uricosuric properties. Pharma- ceutisch Weekblad (in press)Google Scholar
  4. 4.
    Gresser U, Adjan M, Zöllner N (1991) Deficient benzbromarone elimination from plasma: evidence for a new genetically determined polymorphism with an autosomal recessiv inheritance. Adv Exp Med Biol 309A: 157–160Google Scholar
  5. 5.
    Gresser U, Gathof BS (1991) Epidemiology of hyperuricaemia. In: Gresser U, Zöllner N (eds) Urate deposition in man and its clinical consequences. Springer, Berlin, Heidelberg, New York, pp 82–96Google Scholar
  6. 6.
    Gresser U, Gathof BS, Zöllner N (1990) Uric acid levels in Southern Germany 1989. A comparison with studies from 1962,1971 and 1984. Klin Wochenschr 68: 1222–1228CrossRefGoogle Scholar
  7. 7.
    Gresser U, Zöllner N (1989) Uricosuric effect of irtemazole in healthy subjects. Klin Wochenschr 67: 971–975PubMedCrossRefGoogle Scholar
  8. 8.
    Kamilli I, Gresser U, Hahn D, Vogl T, Zöllner N (1992) Urate deposition: scintigraphy and magnetic resonance imaging. Br J Rheumatol 31: 135Google Scholar
  9. 9.
    Kamilli I, Gresser U, Pellkofer T, Löffler W, Zöllner N (1989) Uricosuric effect of irtemazole in hyperuricemic patients without and with renal insufficiency. Z Rheumatol 48: 307–312PubMedGoogle Scholar

Copyright information

© Springer Verlag, Berlin Heidelberg 1993

Authors and Affiliations

  • U. Gresser

There are no affiliations available

Personalised recommendations